Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106, CD20-Targeted CAR T Therapy, in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Very favorable safety profile suitable for outpatient treatment, high complete response rate and strong durability observed, including patients with Waldenstrom macroglobulinemia and those who received prior CD19-directed CAR T therapy Expect to dose first patient in multicenter clinical trial this quarter Data presented at 2022 Tandem Meetings I Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.



Please enter your comment!
Please enter your name here